

PATIENT INFORMATION

Name:		SSN:	DOB:
Address:	City:	State:	ZIP:
Home Phone:	Cell:	Email:	Gender: Female Male

CLINICAL INFORMATION

Diagnosis: ☐ Rheumatoid Arthritis ☐ Psoriatic Arthritis ☐ Ankylosing Spondylitis ☐ Juvenile Rheumatoid Arthritis ☐ Iridocyclitis (Uveitis) ☐ Other: _____

Allergies: _____ Weight: _____ Height: _____

TB Test Result: _____ Date: _____ HepB Test Result: _____ Date: _____

Prior Failed Meds: ☐ Actemra® ☐ Cimzia® ☐ Cosentyx® ☐ Enbrel® ☐ Humira® ☐ Kevzara® ☐ Orencia® ☐ Otezla® ☐ Other: _____

Prior Methotrexate/Oral Systemic Medications: ☐ Yes ☐ No ☐ Contraindicated

INSURANCE INFORMATION (or attach copy of the cards)

Primary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:
--------------------	----------------	---------------	-----------	----------

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

ACTEMRA® (tocilizumab) ☐ 80 mg/4 mL ☐ 200 mg/10 mL ☐ 400 mg/20 mL ☐ 162 mg/0.9 mL PFS ☐ 162 mg/0.9 mL pen ☐ Infuse ☐ 4 mg/kg ☐ 8 mg/kg IV every 4 weeks ☐ Inject 162 mg SUBQ (☐ Every other week ☐ Every week) Qty: _____ Refills: _____	ENBREL® (etanercept) ☐ Mini cartridge ☐ PFS ☐ Autoinjector ☐ Vial ☐ 25 mg ☐ 50 mg ☐ Once weekly SUBQ ☐ Twice weekly SUBQ Qty: ☐ 4 ☐ 8 Refills: _____	RINVOQ® (upadacitinib) extended-release tablets ☐ 15 mg ☐ 30 mg Once daily PO with or without food Qty: _____ Refills: _____
AMJEVITA™ (adalimumab-atto) ☐ SureClick 40 mg/0.8 mL ☐ PFS 20 mg/0.4 mL ☐ PFS 40 mg/0.8 mL ☐ Inject 40 mg every other week and _____ mg every other week Qty: _____ Refills: _____	HUMIRA® (adalimumab) ☐ Pen ☐ PFS ☐ Citrate free (CF) ☐ Original formula ☐ 40 mg SUBQ every other week ☐ 40 mg SUBQ once a week Qty: 28 days Refills: _____	SIMLANDI® (adalimumab-ryvk) 40 mg PFS ☐ Inject SUBQ 40 mg every other week Qty: 1 Refills: _____
BENLYSTA® (belimumab) Vials: ☐ 120 mg ☐ 400 mg 200 mg ☐ Autoinjector ☐ PFS ☐ Infuse _____ mg (10 mg/kg/dose) IV at weeks 0, 2, 4, then every 4 weeks thereafter ☐ Maintenance: Infuse _____ mg (10 mg/kg/dose) IV every 4 weeks ☐ Induction: Inject 400 mg SUBQ once weekly for 4 doses then 200 mg SUBQ once a week thereafter. ☐ Maintenance: Inject 200 mg SUBQ once a week Qty: 4 Week Supply Refills: _____	INFLECTRA® (infliximab-dyyb) 100 mg vials ☐ 3 mg/kg ☐ 5 mg/kg ☐ 10 mg/kg ☐ Induction: Give dose as an IV infusion at 0, 2, and 6 weeks Qty: _____ Refills: _____ ☐ Maintenance: Give dose as an IV infusion every _____ weeks Qty: _____ Refills: _____	SIMPONI® (golimumab) 50 mg ☐ PFS ☐ Autoinjector Inject SUBQ once a month Qty: 1 Refills: _____
BIMZELX® (bimekizumab-bkzx) 160 mg ☐ PFS ☐ Pen ☐ Inject 160 mg SUBQ every 4 weeks Qty: 1 Refills: _____	KEVZARA® (sarilumab) ☐ Pen ☐ PFS ☐ 150 mg ☐ 200 mg Dosing: Inject SUBQ every 2 weeks. Qty: 2 Refills: _____	SKYRIZI™ (risankizumab-rzaa) ☐ PFS ☐ Pen ☐ Inject 150 mg (1 injection) SUBQ at Week 0, Week 4, and then every 12 weeks Qty: 1 Refills: _____
CIMZIA® (certolizumab pegol) PFS Induction: ☐ Inject 100 mg SUBQ at weeks 2 and 4 ☐ Inject 400 mg (2 x 200 mg) SUBQ at weeks 0, 2, and 4 Qty: 6 Refills: _____ Maintenance: ☐ 50 mg SUBQ every other week ☐ 100 mg SUBQ every other week ☐ 200 mg SUBQ every 2 weeks ☐ 400 mg (2 x 200 mg) SUBQ every 4 weeks ☐ 400 mg (2 x 200 mg) SUBQ every 2 weeks Qty: _____ Refills: _____	OLUMIANT® (baricitinib) ☐ 1 mg tablet ☐ 2 mg tablet ☐ Take 1 tablet PO daily Qty: _____ Refills: _____ ☐ Bridge*	STELARA® (ustekinumab) ☐ 45 mg PFS ☐ 90 mg PFS Inject contents of 1 syringe SUBQ on day 0, then week 4, then every 12 weeks Qty: 1 Refills: _____
COSENTYX™ (secukinumab) 75 mg ☐ 75 mg PFS ☐ Induction: Inject 75 mg SUBQ at weeks 0, 1, 2, 3 Qty: 28 days Refills: 0 ☐ Maintenance: Inject 75 mg SUBQ on week 4, then every 4 weeks Qty: 28 days Refills: _____ 150 mg ☐ 150 mg Sensoready® Pen Kit ☐ 150 mg PFS ☐ Induction: Inject 150 mg SUBQ at weeks 0, 1, 2, 3 Qty: 5 Refills: _____ ☐ Maintenance: Inject 150 mg SUBQ on week 4, then every 4 weeks Qty: 28 days Refills: _____ 300 mg ☐ UnoReady Pen (1 x 300 mg/2mL) ☐ Sensoready® Pen Kit (2 x 150 mL) ☐ PFS (2 x 150 mL) ☐ Induction: Inject 300 mg SUBQ at weeks 0, 1, 2, 3 Qty: 28 days Refills: 0 ☐ Maintenance: Inject 300 mg SUBQ on week 4, then every 4 weeks Qty: 28 days Refills: _____	OTEZLA® (apremilast) ☐ Titration Pack: Take PO as directed per package instructions Qty: 1 Pack Refills: 0 ☐ Bridge Pack: Take PO as directed per package instructions Qty: 1 Pack Refills: 0 ☐ Maintenance: 30 mg PO twice daily Qty: 30 days Refills: _____ ☐ Bridge*	TALTZ® (ixekizumab) ☐ Autoinjector ☐ PFS ☐ Citrate free (CF) ☐ Psoriasis Induction: Inject 160 mg (2 x 80 mg injections) SUBQ at week 0; Inject 80 mg at weeks 2, 4, 6, 8, 10, 12 Qty: 8 Refills: _____ ☐ Psoriatic Arthritis Induction: Inject 160 mg (2 x 80 mg injections) SUBQ at week 0 Qty: 2 Refills: 0 ☐ Maintenance: 80 mg SUBQ every 4 weeks Qty: 1 Refills: _____ ☐ Bridge*
	REMICADE® (infliximab) 100 mg vials ☐ Biosimilar authorized ☐ 3 mg/kg ☐ 5 mg/kg ☐ 10 mg/kg ☐ Induction: Give dose as an IV infusion at 0, 2, and 6 weeks Qty: _____ Refills: 2 ☐ Maintenance: Give dose as an IV infusion every _____ weeks Qty: _____ Refills: _____	TREMFYA® (guselkumab) ☐ PFS ☐ Autoinjector ☐ Induction: Inject 100 mg SUBQ weeks 0 and 4 Qty: 1 Refills: 1 ☐ Maintenance: Inject 100 mg SUBQ every 8 weeks Qty: 1 Refills: _____
		XELJANZ® (tofacitinib) ☐ 5 mg tablet ☐ 11 mg XR tabs ☐ Take one 5 mg tablet PO twice daily ☐ Take one 11 mg tablet PO once daily Qty: _____ Refills: _____
		☐ OTHER STRENGTH: SIG/DIRECTIONS: QUANTITY: _____ REFILLS: _____

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution. ☐ Dispense as written

PHYSICIAN INFORMATION

Injection Training: ☐ **Office to Instruct** ☐ **SP to Arrange Teaching**

Prescriber Name:	Phone:	Fax:
Office Contact:	Email:	
Address:	City:	State: ZIP:
NPI #:	Tax ID#:	Ship To: ☐ Patient ☐ MD Office
Prescriber Signature:	Date:	